

NM

Report of the Directors and
Unaudited Financial Statements for the Period 25 July 2021 to 31 July 2022
for
The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

SATURDAY



AC8RXAQW

A28

29/07/2023

#46

COMPANIES HOUSE

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Contents of the Financial Statements
for the Period 25 July 2021 to 31 July 2022

	Page
Company Information	1
Report of the Directors	2
Chartered Accountants' Report	4
Income Statement	6
Other Comprehensive Income	7
Balance Sheet	8
Statement of Changes in Equity	10
Notes to the Financial Statements	11
Detailed Profit and Loss Account	12

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Company Information
for the Period 25 July 2021 to 31 July 2022

DIRECTORS:

Dr A El Baghdady
J A El Baghdady
Y Baghdady

REGISTERED OFFICE:

Hamilton House
Mabledon Place
London
WC1H 9BB

REGISTERED NUMBER:

12729033 (England and Wales)

ACCOUNTANTS:

Reed Accounts & Tax Limited
Chartered Accountant
Hallings Hatch
Parkgate Road
Dorking
Surrey
RH5 5DY

Report of the Directors
for the Period 25 July 2021 to 31 July 2022

The directors present their report with the financial statements of the company for the period 25 July 2021 to 31 July 2022.

DIRECTORS

The directors shown below have held office during the whole of the period from 25 July 2021 to the date of this report.

Dr A El Baghdady
Y Baghdady

Other changes in directors holding office are as follows:

J A El Baghdady - appointed 25 April 2022

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Report of the Directors
for the Period 25 July 2021 to 31 July 2022

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:



.....
Dr A El Baghdady - Director

Date: 5/6/23

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
The Middle East Association of
Pharmaceutical Medicine Professionals
CIC


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of The Middle East Association of Pharmaceutical Medicine Professionals CIC for the period ended 31 July 2022 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at <http://www.icaew.com/en/membership/regulations-standards-and-guidance>.

This report is made solely to the Board of Directors of The Middle East Association of Pharmaceutical Medicine Professionals CIC, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of The Middle East Association of Pharmaceutical Medicine Professionals CIC and state those matters that we have agreed to state to the Board of Directors of The Middle East Association of Pharmaceutical Medicine Professionals CIC, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than The Middle East Association of Pharmaceutical Medicine Professionals CIC and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that The Middle East Association of Pharmaceutical Medicine Professionals CIC has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of The Middle East Association of Pharmaceutical Medicine Professionals CIC. You consider that The Middle East Association of Pharmaceutical Medicine Professionals CIC is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the financial statements of The Middle East Association of Pharmaceutical Medicine Professionals CIC. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Reed Accounts & Tax Limited
Chartered Accountant
Hallings Hatch
Parkgate Road
Dorking
Surrey
RH5 5DY

This page does not form part of the statutory financial statements

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Date: 07/06/2023

This page does not form part of the statutory financial statements

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Income Statement
for the Period 25 July 2021 to 31 July 2022

	Period 25.7.21 to 31.7.22 £	Period 9.7.20 to 24.7.21 £
TURNOVER	-	-
Administrative expenses	1,274	-
OPERATING LOSS and LOSS BEFORE TAXATION	(1,274)	-
Tax on loss	-	-
LOSS FOR THE FINANCIAL PERIOD	(1,274)	-

The notes form part of these financial statements

100-100000

100-100000

100-100000

100-100000
100-100000
100-100000

100-100000
100-100000

100-100000

100-100000

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Other Comprehensive Income
for the Period 25 July 2021 to 31 July 2022

	Notes	Period 25.7.21 to 31.7.22 £	Period 9.7.20 to 24.7.21 £
LOSS FOR THE PERIOD		(1,274)	-
OTHER COMPREHENSIVE INCOME		-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		<u>(1,274)</u>	<u>-</u>

The notes form part of these financial statements

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a presentation of the results of the study. It includes tables and graphs showing the data and the findings of the research.

4. The fourth part of the report is a discussion of the results and their implications. It discusses the strengths and limitations of the study and provides recommendations for future research.

5. The fifth part of the report is a conclusion and a summary of the findings. It provides a final statement on the results of the study and the overall conclusions.

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a presentation of the results of the study. It includes tables and graphs showing the data and the findings of the research.

4. The fourth part of the report is a discussion of the results and their implications. It discusses the strengths and limitations of the study and provides recommendations for future research.

5. The fifth part of the report is a conclusion and a summary of the findings. It provides a final statement on the results of the study and the overall conclusions.

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a presentation of the results of the study. It includes tables and graphs showing the data and the findings of the research.

4. The fourth part of the report is a discussion of the results and their implications. It discusses the strengths and limitations of the study and provides recommendations for future research.

5. The fifth part of the report is a conclusion and a summary of the findings. It provides a final statement on the results of the study and the overall conclusions.

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a presentation of the results of the study. It includes tables and graphs showing the data and the findings of the research.

4. The fourth part of the report is a discussion of the results and their implications. It discusses the strengths and limitations of the study and provides recommendations for future research.

5. The fifth part of the report is a conclusion and a summary of the findings. It provides a final statement on the results of the study and the overall conclusions.

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a presentation of the results of the study. It includes tables and graphs showing the data and the findings of the research.

4. The fourth part of the report is a discussion of the results and their implications. It discusses the strengths and limitations of the study and provides recommendations for future research.

5. The fifth part of the report is a conclusion and a summary of the findings. It provides a final statement on the results of the study and the overall conclusions.

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC (Registered number: 12729033)

Balance Sheet
31 July 2022

	Notes	31.7.22 £	24.7.21 £
CURRENT ASSETS			
Cash at bank		3,726	-
CREDITORS			
Amounts falling due within one year	4	5,000	-
NET CURRENT LIABILITIES		(1,274)	-
TOTAL ASSETS LESS CURRENT LIABILITIES		(1,274)	-
RESERVES			
Retained earnings		(1,274)	-
		(1,274)	-

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 July 2022.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 July 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The notes form part of these financial statements

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC (Registered number: 12729033)

Balance Sheet - continued
31 July 2022

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on
..... 05/06/2023 and were signed on its behalf by:



.....
Dr A El Baghdady - Director

The notes form part of these financial statements

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Statement of Changes in Equity
for the Period 25 July 2021 to 31 July 2022

	Retained earnings £	Total equity £
Changes in equity		
Balance at 24 July 2021	-	-
Changes in equity		
Total comprehensive income	(1,274)	(1,274)
Balance at 31 July 2022	(1,274)	(1,274)

The notes form part of these financial statements

1. STATUTORY INFORMATION

The Middle East Association of Pharmaceutical Medicine Professionals CIC is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 (2021 - NIL).

4. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.7.22	24.7.21
	£	£
Other creditors	5,000	-
	<u>5,000</u>	<u>-</u>

The Middle East Association of
Pharmaceutical Medicine Professionals
CIC

Detailed Profit and Loss Account
for the Period 25 July 2021 to 31 July 2022

	Period 25.7.21 to 31.7.22		Period 9.7.20 to 24.7.21	
	£	£	£	£
Income		-		-
Expenditure				
Rent		1,201		-
		<hr/>		<hr/>
		(1,201)		-
Finance costs				
Bank charges		73		-
		<hr/>		<hr/>
NET LOSS		<hr/> <hr/> (1,274)		<hr/> <hr/> -

This page does not form part of the statutory financial statements